Ocular pharmacokinetics, safety and efficacy of intracameral moxifloxacin 0.5% solution in a rabbit model

Current Eye Research

Volumn 38, Issue 4, 2013, Pages 472-479

  Asena, Leyla ^a,b   Akova, Yonca A ^a,c   Goktaş, Mustafa T ^d   Bozkurt, Atilla ^d   Yaşar, Ümit ^d   Karabay, Gülten ^a   Demiralay, Ebru ^a  

^a BASKENT UNIVERSITY   (Turkey)

^b Agri Government Hospital   (Turkey)

^c Ophthalmology Unit   (Turkey)

^d HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Endophthalmitis; Intracameral moxifloxacin; Pharmacokinetics; Prophylaxis; Toxicity

Indexed keywords

MOXIFLOXACIN;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTERIOR EYE CHAMBER; AQUEOUS HUMOR; ARTICLE; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; CORNEA; CORNEA ENDOTHELIUM; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; ENDOPHTHALMITIS; ENDOPLASMIC RETICULUM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IRIS; MINIMUM INHIBITORY CONCENTRATION; MITOCHONDRION; NONHUMAN; PHACOEMULSIFICATION; PRIORITY JOURNAL; RABBIT MODEL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIA; VITREOUS BODY;

ANIMALS; ANTI-BACTERIAL AGENTS; AQUEOUS HUMOR; AZA COMPOUNDS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOPHTHALMITIS; EPITHELIUM, CORNEAL; EYE INFECTIONS, BACTERIAL; INJECTIONS, INTRAOCULAR; MICROSCOPY, ELECTRON, TRANSMISSION; PHACOEMULSIFICATION; QUINOLINES; RABBITS; STAPHYLOCOCCAL INFECTIONS; STREPTOCOCCAL INFECTIONS; VITREOUS BODY;

EID: 84887421805     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2012.763101     Document Type: Article

References (33)

1. Taban M, Behrens A, Newcomb RL, Nobe MY, Saedi G, Sweet PM, et al. Acute endophthalmitis following cataract surgery: a systematic review of the literature. Arch Ophthalmol 2005;123:613-620.
2. Kernt M, Neubauer AS, Liegl RG, Lackerbauer CA, Eibl KH, Alge CS, et al. Intracameral moxifloxacin: in vitro safety on human ocular cells. Cornea 2009;28:553-561.
3. Ciulla TA, Starr MB, Masket S. Bacterial endophthalmitis prophylaxis for cataract surgery: an evidence-based update. Ophthalmology 2002;109:13-24.
4. Endophthalmitis Study Group, European Society of Cataract & Refractive Surgeons. Prophylaxis of postoperative endophthalmitis following cataract surgery: results of the ESCRS multicenter study and identification of risk factors. J Cataract Refract Surg 2007;33:978-988.
5. Masket S. Preventing, diagnosing, and treating endophthalmitis. J Cataract Refract Surg 1998;24:725-726.
6. Axer-Siegel R, Stiebel-Kalish H, Rosenblatt I, Strassmann E, Yassur Y, Weinberger D. Cystoid macular edema after cataract surgery with intraocular vancomycin. Ophthalmology 1999;106:1660-1664.
7. Villada JR, Vicente U, Javaloy J, Alio JL. Severe anaphylactic reaction after intracameral antibiotic administration during cataract surgery. J Cataract Refract Surg 2005;31:620-621.
8. Filip M, Dragne C, Filip A, Magureanu M, Zemba M, Asandi R. Toxic anterior segment syndrome. Oftalmologia 2006;50:27-29.
9. O'Brien TP, Arshinoff SA, Mah FS. Perspectives on antibiotics for postoperative endophthalmitis prophylaxis: potential role of moxifloxacin. J Cataract Refract Surg 2007;33:1790-1800.
10. Kowalski RP, Romanowski EG, Mah FS, Yates KA, Gordon YJ. Intracameral Vigamox (moxifloxacin 0.5%) is non-toxic and effective in preventing endophthalmitis in a rabbit model. Am J Ophthalmol 2005;140:497-504.
11. Lane SS, Osher RH, Masket S, Belani S. Evaluation of the safety of prophylactic intracameral moxifloxacin in cataract surgery. J Cataract Refract Surg 2008;34:1451-1459.
12. Espiritu CR, Caparas VL, Boliano JG. Safety of prophylactic intracameral moxifloxacin 0.5% ophthalmic solution in cataract surgery patients. J Cataract Refract Surg 2007;33:63-68.
13. Giingor SG, Akova YA, Bozkurt A, Yasar U, Babaoglu MO, Cetinkaya A, et al. Aqueous humour penetration of moxifloxocin and gatifloxacin eye drops in different dosing regimens before phacoemulsification surgery. Br J Ophthalmol 2010;95:1272-1275.
14. Yagci R, Oflu Y, Dincel A, Kaya E, Yagci S, Bayar B, et al. Penetration of second-, third-, and fourth-generation topical fluoroquinolone into aqueous and vitreous humour in a rabbit endophthalmitis model. Eye (Lond) 2007;21:990-994.
15. Gabrielsson J, Weiner D. Non-compartmental analysis. Methods Mol Biol 2012;929:377-389.
16. Kowalski RP, Dhaliwal DK, Karenchak LM, Romanowski EG, Mah FS, Ritterband DC, et al. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol 2003;136:500-505.
17. Metzler K, Hansen GM, Hedlin P, Harding E, Drlica K, Blondeau JM. Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and-resistant Staphylococcus aureus. Int J Antimicrob Agents 2004;24:161-167.
18. Blondeau JM, Zhao X, Hansen G, Drlica K. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2001;45:433-438.
19. Learning DV. Practice styles and preferences of U. S. ASCRS members - 2005 survey. ASCRS Symposium on Cataract, IOL and Refractive Surgery; March 2006; San Francisco, California, USA.
20. Montan PG, Wejde G, Setterquist H, Rylander M, Zetterstrom C. Prophylactic intracameral cefuroxime: evaluation of safety and kinetics in cataract surgery. J Cataract Refract Surg 2002;28:982-987.
21. Han DP, Wisniewski SR, Wilson LA, Barza M, Vine AK, Doft BH, et al. Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study. Am J Ophthalmol 1996;122:1-17.
22. Kowalski RP, Pandya AN, Karenchak LM, Romanowski EG, Husted RC, Ritterband DC, et al. An in vitro resistance study of levofloxacin, ciprofloxacin and ofloxacin using keratitis isolates of Staphylococcus aureus and Pseudomonas aeruginosa. Ophthalmology 2001;108:1826-1829.
23. Benz MS, Scott IU, Flynn Jr HW, Unonius N, Miller D. Endophthalmitis isolates and antibiotic sensitivities: a 6-year review of culture-proven cases. Am J Ophthalmol 2004;137:38-42.
24. Murphy CC, Nicholson S, Quah SA, Batterbury M, Neal T, Kaye SB. Pharmacokinetics of vancomycin following intracameral bolus injection in patients undergoing phacoemulsification cataract surgery. Br J Ophthalmol 2007;91:1350-1353.
25. Bergogne-Berezin E. Clinical role of protein binding of quinolones. Clin Pharmacokinet 2002;41:741-750.
26. Oh C, Saville BA, Cheng YL, Rootman DS. A compartment model for the ocular pharmacokinetics of cyclosporine in rabbits. Pharm Res 1995;12:433-437.
27. Becker B, Constant MA. Species variation in facility of aqueous outflow. Am J Ophthalmol 1956;42:189-194.
28. Schoenwald RD. Ocular pharmacokinetics. Textbook of ocular pharmacology. 3rd ed. Philadelphia: Lipincott-Raven; 1997.
29. Kim DH, Stark WJ, O'Brien TP, Dick JD. Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients. Ophthalmology 2005;112:1992-1996.
30. Schentag J. Pharmacokinetic and pharmacodynamic predictors of antimicrobial efficacy: moxifloxacin and Streptococcus pneumoniae. J Chemother 2002;14:13-21.
31. Kim SY, Park YH, Lee YC. Comparison of the effect of intracameral moxifloxacin, levofloxacin and cefazolin on rabbit corneal endothelial cells. Clin Experiment Ophthalmol 2008;36:367-370.
32. Arbisser LB. Safety of intracameral moxifloxacin for prophylaxis of endophthalmitis after cataract surgery. J Cataract Refract Surg 2008;3:1114-1120.
33. Arshinoff SA. Advantages and use of intracameral moxifloxacin for bacterial prophylaxis in cataract surgery. ASCRS Symposium on Cataract, IOL and Refractive Surgery; April 2007; San Diego, CA, USA.